{'fraction_non_alphanumeric': 0.015051740357478834, 'fraction_numerical': 0.0, 'mean_word_length': 6.823529411764706, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Quantitative electroencephalographic evaluations of electrophysiological biomarkers and impaired functional networks of older adults diagnosed with dementia

Alzheimer’s disease (AD) is a neurodegenerative disorder attributable to neurofibrillary tangles, senile neuritic plaques, and a reduction of neurons and synapses. Because the etiopathogenesis of AD is complex and its associated risk factors are not well understood, clinical interventions to effectively treat AD are being developed. Thus, interventional strategies to delay disease progression have been the focus of numerous pharmacologically oriented trials. Recognition of near‐infrared photobiomodulation as having disease modifying properties in the treatment of age‐related dementia has been reported by Paul Chazot PhD, Senior Lecturer in Neuropharmacology at Durham University. The utilization of electrophysiological biomarkers and dysregulated functional networks may allow for neuromodulation applications to curtail symptomatic progression and therefore non‐invasive prophylactic strategies.